 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...3637383940414243444546...123124» |
- Votrient (pazopanib) / Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer
EZH2 mediated kinome reprogramming drives AR phosphorylation and activation in receptor tyrosine kinase inhibitors resistant renal carcinoma models (Section 16; Poster Board #11) - Mar 14, 2023 - Abstract #AACR2023AACR_6116;
Overall, our results suggest that AR activation is driven by phosphorylation induced by EZH2 dependent kinome reprogramming. Untangling the cross talk between AR and EZH2 in RTKI resistant RCC will provide the rationale for novel therapeutic strategies to improve the clinical outcome in patients with this disease.
- Cyramza (ramucirumab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
HER3 expression after systemic therapy and clinical characteristics in patients with hepatocellular carcinoma (Section 42; Poster Board #9) - Mar 14, 2023 - Abstract #AACR2023AACR_5926;
In this study, 47% of pts were HER3 2+/3+ at post-treatment. In paired analysis, half of pts upregulated HER3 expression after systemic therapy including TKIs, suggesting HER3 might be one of the factors associated with resistance to systemic therapy.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Rubraca (rucaparib) / Clovis
Serine/threonine kinase 39 (STK39) regulates cancer stemness through regulating PARP-mediated SOX2/OCT4 expression in hepatocellular carcinoma (Section 4; Poster Board #16) - Mar 14, 2023 - Abstract #AACR2023AACR_5418;
In summary, STK39 regulates cancer stemness and drug resistance by directly modulating PARP1-mediated SOX2/OCT4 expression via chromatin remodelling. Targeting STK39/PARP1 signaling cascade alone or in combination with molecular targeted drugs including rucaparib and lenvatnib can be the potential therapeutic strategy for treatment of this deadly disease.
- Beleodaq (belinostat) / Aurobindo, Spectrum Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Targeting of AKT/?-catenin signaling pathways driven hepatocellular carcinoma cell lines by combined treatment of HDAC and multi-kinase inhibitors (Section 8; Poster Board #2) - Mar 14, 2023 - Abstract #AACR2023AACR_5208;
In addition, the percentage of apoptotic cells was significantly increased and showed a cell cycle arrest in the G0/G1 phase of Hep-G2 cells after 48 hours of combined treatment as confirmed by flow cytometry. All in all, our data show that targeting AKT/?-catenin driven HCC progression can be targeted by Lenvatinib and Belinostat combined treatment.
- fostroxacitabine bralpamide (MIV-818) / Medivir
A triple combination of fostrox (MIV-818) with immune checkpoint and kinase inhibition shows increased anti-tumor efficacy in vivo (Section 14; Poster Board #27) - Mar 14, 2023 - Abstract #AACR2023AACR_4913;
P1/2
The triple combination of fostrox with anti-PD1 and lenvatinib showed enhanced efficacy in a nonclinical tumor model, and changes in TILs were consistent with increased immune-mediated anti-tumor activity. The results indicate a potential for increased anti-tumor efficacy using a triple combination of fostrox plus checkpoint inhibition and anti-angiogenic therapy.1The study was approved by the Institutional Animal Care and Use Committee (IACUC) of CrownBio UK, and conducted in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)
- Biochemical inhibition profiles of 370 wild type human kinases provide a basis for selecting alternative combinations of EGFR and VEGFR inhibitors (Section 14; Poster Board #1) - Mar 14, 2023 - Abstract #AACR2023AACR_4887;
Kinase inhibition profiles were measured for 7 agents that were candidate alternatives for cediranib or erlotinib, including: vandetanib, erdafitinib, axitinib, lenvatinib, cabozantinib, poziotinib, and mobocertinib (note: Cmax values varied 58-fold among the drugs)...This project was funded in part with federal funds from the NCI, NIH, under contract no. HHSN261201500003I.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), CBA-1205 / Chiome Biosci
Synergistic and long-lasing anti-tumor efficacy of CBA-1205, a novel glycoengineered humanized antibody targeting DLK-1, in combination with lenvatinib in human HCC xenograft models. (Section 25; Poster Board #1) - Mar 14, 2023 - Abstract #AACR2023AACR_4008;
Similar results were obtained with CBA-1205 at 1 mg/kg dosage in combination with lenvatinib at 10 mg/kg dosage in HepG2 xenograft model. In conclusion, we demonstrated synergistic and long-lasting anti-tumor efficacy of CBA-1205 in combination with lenvatinib in two different HCC pre-clinical models suggesting that the combination could be a new treatment option for unresectable advanced HCC.
- eribulin mesylate (E7386) / Eisai, PRISM Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
E7386, a selective inhibitor of the interaction between ?-catenin and CREB-binding protein (CBP), enhances antitumor activity in combination with lenvatinib (LEN), and LEN + anti-PD-1 antibody in a preclinical tumor model (Section 24; Poster Board #9) - Mar 14, 2023 - Abstract #AACR2023AACR_3985;
E7386 suppressed the Wnt signal that was activated with LEN in tumor endothelial cells and E7386 + LEN, and the triple combination also decreased the immunosuppressive myeloid cells that were increased with LEN, and LEN + anti-PD-1 Ab. These activities of E7386 on the tumor microenvironment could provide unique mechanisms of antitumor activity for this triple combination in preclinical tumor models.
- eribulin mesylate (E7386) / Eisai, PRISM Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
E7386, a selective inhibitor of the interaction between ?-catenin and CREB-binding protein (CBP), in combination with lenvatinib (LEN), exerts antitumor activity in preclinical tumor models with prior immune checkpoint inhibitor (ICI)-based combination treatment (Section 24; Poster Board #2) - Mar 14, 2023 - Abstract #AACR2023AACR_3978;
P1b
E7386 + LEN combination shows antitumor activity in the mouse KLN 205 lung tumor model when there is prior ICI-based (CTLA-4 + PD-1 or AFL + PD-1) combination treatment. Further, E7386 + LEN shows enhanced antitumor activity with prior AFL + PD-1; possibly due to activation of Wnt-signaling pathway during prior treatments.
- galunisertib (LY2157299) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Heart-sparing ALK5 inhibitor for treatment of gastrointestinal and liver cancers (Section 18; Poster Board #18) - Mar 14, 2023 - Abstract #AACR2023AACR_3904;
No heart valve toxicity was observed when benchmarked against galunisertib (systemic ALK5 inhibitor) in toxicity studies with repeated daily dosing. These data suggest that our liver-targeted/heart-sparing approach may allow more robust target engagement compared to systemic ALK5 inhibitors through higher dose or more frequent dosing.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma (Section 21; Poster Board #11) - Mar 14, 2023 - Abstract #AACR2023AACR_3816;
CDK6 blockade impedes the lenvatinib-induced activation of the ERK/YAP/CDK6/?-catenin signaling cascade. Targeting CDK6 with palbociclib in combination with lenvatinib may be a novel therapeutic strategy against HCC.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Reversal of lenvatinib resistance by curcumin via EGFR signaling pathway in hepatocellular carcinoma (Section 21; Poster Board #4) - Mar 14, 2023 - Abstract #AACR2023AACR_3809;
Targeting CDK6 with palbociclib in combination with lenvatinib may be a novel therapeutic strategy against HCC. We provide the first evidence that curcumin could overcome lenvatinib resistance in HCC cells via suppression of EGFR and its downstream targets, which can offer a novel therapeutic strategy in HCC.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Evaluation of an AKT-1 antisense oligonucleotide in combination with Lenvatinib and Everolimus in Renca-luciferase syngeneic orthotopic murine tumor model (Section 24; Poster Board #21) - Mar 14, 2023 - Abstract #AACR2023AACR_2607;
Three drugs combination of Archexin, Lenvatinib and Everolimus, demonstrated superior anti-tumor efficacy compared to the two-drug combination currently used in the clinic. This finding suggests the three-drug combination warrant investigation in the clinical trial in the patients with advanced renal cancer.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Focal adhension kinase (FAK) confers lenvatinib resistance in hepatocellular carcinoma via regulation of lysine deficient protein kinase 1(WNK1) (Section 14; Poster Board #15) - Mar 14, 2023 - Abstract #AACR2023AACR_2492;
In addition, overexpression of WNK1 desensitized parental HCC cells (Hep3B-P and Huh7-P) to lenvatinib treatment. Conclusively, our results establish a crucial role and novel mechanism of FAK in lenvatinib resistance, and suggest that targeting the FAK/WNK1 axis is a promising therapeutic strategy in HCC patients showing lenvatinib resistance.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
The potential of 18?-glycyrrhetinic acid benefit lenvatinib induced cytotoxicity on hepatocellular carcinoma (Section 43; Poster Board #18) - Mar 14, 2023 - Abstract #AACR2023AACR_2312;
Additionally, the liver function and normal tissue pathology may not affect by combination of lenvatinib and 18?-GA. To conclude, our result demonstrated that 18?-GA may sensitize HCC to lenvatinib via inactivation of PI3K/AKT signaling pathway and induction of extrinsic/intrinsic apoptosis signaling.
- |||| Clinical: Well, axi pembro, nivo cabo and lenva pembro met OS endpoint in RCC first line, but axi avelumab did not. (Twitter) - Mar 14, 2023
- | Opdivo (nivolumab) / BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial: Neoantigen Derived DCs as Cancer Treatment (clinicaltrials.gov) - Mar 14, 2023
P1, N=12, Not yet recruiting, Sponsor: National Health Research Institutes, Taiwan
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Sustained antitumor response to lenvatinib with weekend-off and alternate-day administration in chemotherapy-refractory thymic carcinoma: a case report. (Pubmed Central) - Mar 13, 2023
Consequently, the patient exhibited a durable response to lenvatinib, with a 17-month progression-free survival without any severe or intolerable AEs. The present case suggests that maintaining lenvatinib dose intensity using such alternative administration regimens contributes to favorable clinical outcomes in thymic carcinoma.
- | hydroxychloroquine / Generic mfg., Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Genome-Scale CRISPR Screen Identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma. (Pubmed Central) - Mar 13, 2023
Importantly, in clinical HCC samples, where lenvatinib was used as the first line or adjuvant therapy, LAPTM5 expression positively correlated with lenvatinib sensitivity, implying it as a biomarker to predict patient response to lenvatinib. In conclusion, the combinational therapy targeting autophagy represented a promising strategy to overcome lenvatinib resistance in HCC, and LAPTM5 expression could provide potential guidance for clinical interference.
- || fostroxacitabine bralpamide (MIV-818) / Medivir, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: Första patienten doserad i fas 2a-delen av Medivirs studie med fostrox i kombination med Lenvima[® ] https://t.co/GLijhLJf4H (Twitter) - Mar 13, 2023
- ||| E7386 / Eisai, PRISM Pharma
Enrollment change, Trial completion date, Trial primary completion date: KEYNOTE-C83: A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors (clinicaltrials.gov) - Mar 13, 2023
P1b/2, N=156, Recruiting, Sponsor: Eisai Inc.
In conclusion, the combinational therapy targeting autophagy represented a promising strategy to overcome lenvatinib resistance in HCC, and LAPTM5 expression could provide potential guidance for clinical interference. N=108 --> 156 | Trial completion date: May 2025 --> Sep 2025 | Trial primary completion date: May 2025 --> Sep 2025
- || volrustomig (MEDI5752) / AstraZeneca
Trial completion date, Trial primary completion date: A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Mar 10, 2023
P1b, N=70, Recruiting, Sponsor: MedImmune LLC
N=108 --> 156 | Trial completion date: May 2025 --> Sep 2025 | Trial primary completion date: May 2025 --> Sep 2025 Trial completion date: Apr 2024 --> Mar 2025 | Trial primary completion date: Apr 2024 --> Mar 2025
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: CheckMate 9DW: A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 10, 2023
P3, N=732, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Apr 2024 --> Mar 2025 | Trial primary completion date: Apr 2024 --> Mar 2025 Trial completion date: Jan 2025 --> Jun 2025 | Trial primary completion date: May 2024 --> Jun 2025
- |||||| rulonilimab (F520) / Lunan Pharma
Enrollment open, Trial initiation date, Combination therapy: the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 10, 2023
P2/3, N=576, Recruiting, Sponsor: Shandong New Time Pharmaceutical Co., LTD
Trial completion date: Jan 2025 --> Jun 2025 | Trial primary completion date: May 2024 --> Jun 2025 Not yet recruiting --> Recruiting | Initiation date: Aug 2022 --> Nov 2022
- | Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD), sorafenib / Generic mfg.
Journal: EGFR and Lyn inhibition augments regorafenib induced cell death in sorafenib resistant 3D tumor spheroid model. (Pubmed Central) - Mar 9, 2023
Importantly, combined inhibition of EGFR and Lyn kinase in sorafenib resistant tumor spheroids are effective in inducing cell death. Our model proved to be an affordable and useful model to mimic drug resistant tumor microenvironment in HCC and provided novel insights into candidates for new combinational therapies.
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal, Real-world evidence, Real-world: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort. (Pubmed Central) - Mar 9, 2023
Atezolizumab plus bevacizumab showed good efficacy and safety in patients with unresectable HCC and partially advanced liver cirrhosis in a real-world setting. Moreover, the NLR was able to predict response to atezolizumab/bevacizumab treatment and may guide patient selection.
- A Systematic Literature Review of Patient-Reported Outcomes in Phase III Randomized Controlled Trials of Hepatocellular Carcinoma in a First-Line Setting () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1066;
Treatment of advanced HCC requires consideration of HRQOL. First-line systematic therapies may delay functional decline in advanced hepatocellular carcinoma by improving HRQOL in clinically relevant domains compared with sorafenib.
- A Network Meta-Analysis of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_977;
Atezolizumab plus bevacizumab was confirmed to be an effective first-line treatment to improve survival in patients with advanced HCC. The promising results of immunotherapy combinations with TKIs and other agents indicate the availability of more first-line options in the near future for advanced HCC patients.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Real-World Rearranged during Transfection [RET]-Alteration Testing, Treatment and Referral Patterns of Patients with Medullary and Papillary Thyroid Cancer [MTC, PTC] in Taiwan () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_829;
Of those, 50% of MTC patients received Sorafenib and 61% of PTC patients received Lenvatinib. Despite early access to RET -targeted treatments in Taiwan, RET -alteration testing was infrequent and could be improved to identify patients who could benefit from such treatments in future.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Homologous cancer cell membrane-camouflaged nanoparticles target drug delivery and enhance the chemotherapy efficacy of hepatocellular carcinoma. (Pubmed Central) - Mar 7, 2023
Lenvatinib (LT) is a Food and Drug Administration (FDA)-approved frontline drug for the treatment of advanced liver cancer and has achieved excellent clinical efficacy...In vivo experiments revealed that the nanodrug showed superior tumor accumulation and therapeutic effects in subcutaneous tumor mice model and could effectively eliminate tumors within 21 days. As a result, it opens up a new way to reduce side effects and improve the specific therapeutic effect of first-line clinical medications to treat tumors.
- | Preclinical, Journal: Advancements in Hepatocellular Carcinoma: Potential Preclinical Drugs and Their Future. (Pubmed Central) - Mar 7, 2023
The United States Food and Drug Administration (FDA) has authorized the usage of a variety of drugs for the treatment of HCC in recent years, involving multi-kinase inhibitors (lenvatinib, regorafenib, ramucirumab, and cabozantinib), immune checkpoint inhibitors (ICIs) (pembrolizumab and nivolumab), and combination therapies like atezolizumab along with bevacizumab...The in-trial agents/drugs, their molecular targets, and possible benefits compared to alternatives, and iii-the current and future status of potential preclinical drugs with novel therapeutic targets for HCC. Consequently, existing drug treatments and novel strategies with their balanced consumption could ensure a promising future for a universal remedy of HCC in the near future.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal, Metastases: Anti-PD-1-based immunotherapy plus lenvatinib to treat advanced gallbladder cancer in the elderly: a case series and review of current literature. (Pubmed Central) - Mar 7, 2023
The combination of tislelizumab and lenvatinib may be a promising treatment for patients with advanced GBC. The efficacy and safety need further confirmation.
- || Biomarker, Review, Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker: Biomarker-driven therapy in endometrial cancer. (Pubmed Central) - Mar 7, 2023
Other treatment regimens being evaluated in NSMP/CNL are hormonal combinations with cyclin-dependent kinase 4/6 inhibitors and letrozole...Treatment de-escalation is being evaluated in POLEmut cases given its favorable prognosis with or without adjuvant therapy. Molecular subtyping has important prognostic and therapeutic implications, and should guide patient management and clinical trial design in endometrial cancer, which is a molecularly driven disease.
- || Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed: Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) (clinicaltrials.gov) - Mar 7, 2023
P2, N=120, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Molecular subtyping has important prognostic and therapeutic implications, and should guide patient management and clinical trial design in endometrial cancer, which is a molecularly driven disease. Recruiting --> Active, not recruiting
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer
Clinical, Metastases: Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study - The Lancet Oncology @DrChoueiri https://t.co/0Taf7jeAEU (Twitter) - Mar 7, 2023
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: Amit Singal, MD, discussed the data from the LEAP-002 trial of #lenvatinib/#pembrolizumab vs lenvatinib in patients with hepatocellular carcinoma. #HCC #lcsm | @UTSWHospitalMed @UTSWNews @utswcancer @docamitgs https://t.co/Y955lKDjsj (Twitter) - Mar 7, 2023
- | Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Retrospective data, Journal: Increased Spleen Volume in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab in Comparison to Lenvatinib: A Retrospective Analysis. (Pubmed Central) - Mar 6, 2023
Atez/Bev treatment could result in an increased spleen volume. Caution is required when managing patients treated with Atez/Bev, especially those with a high NLR.
- | Oncorine (recombinant human adenovirus type 5) / Mergen Ltd., Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Oncolytic virus, Metastases: Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 6, 2023
P1b, N=25, Recruiting, Sponsor: Fudan University
Caution is required when managing patients treated with Atez/Bev, especially those with a high NLR. Not yet recruiting --> Recruiting
- ||| IMBrave251 in HCC : sorafenib or lenvatinib +/- atezolizumab , after failure of atezolizumab + bevacizumab (Twitter) - Mar 4, 2023
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Lenvatinib plus pembrolizumab a new effective combination of targeted agents. (Pubmed Central) - Mar 3, 2023
Not yet recruiting --> Recruiting No abstract available
- | Votrient (pazopanib) / Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Preclinical, Journal: A Novel Preclinical In Vitro 3D Model of Oral Carcinogenesis for Biomarker Discovery and Drug Testing. (Pubmed Central) - Mar 2, 2023
In summary, we successfully established a 3D spheroid model of oral carcinogenesis for biomarker discovery and drug testing. This model is a validated preclinical model for OSCC development and would be suitable for testing a range of chemotherapeutic agents.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: A multifunctional nanotheranostic agent based on Lenvatinib for multimodal synergistic hepatocellular carcinoma therapy with remarkably enhanced efficacy. (Pubmed Central) - Mar 2, 2023
Moreover, the temperature elevation, regenerated hydrogen peroxide (HO), and lower pH of TME could substantially boost the reaction potency of copper Fenton-like chemistry. More importantly, this combined therapy significantly improved the efficacy of LT, provided a multifunctional LT delivery system, and enriched the nanoparticle-augmented multimodal synergistic HCC therapy modality.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, P2 data, Journal, HEOR: Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24?mg/day. (Pubmed Central) - Mar 2, 2023
P2
In Study 211, HRQoL for patients in the lenvatinib 18?mg/day arm was not statistically different from that of patients in the 24?mg/day arm. These data further support the use of the approved lenvatinib starting dose of 24?mg/day in patients with RR-DTC.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-World Effectiveness of Lenvatinib in Hepatocellular Carcinoma Patients with Nonalcoholic Steatohepatitis. (Pubmed Central) - Mar 2, 2023
These data further support the use of the approved lenvatinib starting dose of 24?mg/day in patients with RR-DTC. No abstract available
- ||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial completion date, Trial primary completion date, Metastases: ALIVE: Immunotherapy for Advanced Liver Cancer (clinicaltrials.gov) - Mar 2, 2023
P2/3, N=150, Not yet recruiting, Sponsor: Immunovative Therapies, Ltd.
No abstract available Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Jun 2025
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Checkpoint inhibition, Metastases: Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis. (Pubmed Central) - Mar 1, 2023
Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Jun 2025 Patients with advanced HCC beyond oligometastasis, simultaneous administration of lenvatinib and PD-1 inhibitor led to significant improvements in survival.
- | Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Journal, Metastases: Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients. (Pubmed Central) - Mar 1, 2023
Patients with advanced HCC beyond oligometastasis, simultaneous administration of lenvatinib and PD-1 inhibitor led to significant improvements in survival. Lenvatinib is effective and can be safely used as second-line systemic therapy after progression on atezolizumab plus bevacizumab in patients with advanced HCC in real-world clinical practice.
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Journal, Adverse events: ALBI Grade Is a Predictive Factor of Lenvatinib Treatment Discontinuation due to Adverse Events in Hepatocellular Carcinoma. (Pubmed Central) - Mar 1, 2023
Lenvatinib is effective and can be safely used as second-line systemic therapy after progression on atezolizumab plus bevacizumab in patients with advanced HCC in real-world clinical practice. The ALBI grades may be useful in predicting adverse events caused by lenvatinib in patients with HCC and Child-Pugh A.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Metastases: Combination of Lenvatinib and Proton Beam Therapy in the Management of Patients With Advanced Hepatocellular Carcinoma. (Pubmed Central) - Mar 1, 2023
Our study confirmed the efficacy and safety of concurrent lenvatinib and PBT. Thus, this combination therapy may be a reasonable treatment option for selected patients with advanced HCC in clinical practice.
- | Avastin (bevacizumab) / Roche, IBI-323 / Innovent Biologics, Alecensa (alectinib) / Roche
Biomarker, Trial initiation date, Trial primary completion date: Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC (clinicaltrials.gov) - Mar 1, 2023
P2, N=80, Not yet recruiting, Sponsor: Hunan Province Tumor Hospital
Thus, this combination therapy may be a reasonable treatment option for selected patients with advanced HCC in clinical practice. Initiation date: Jul 2022 --> Mar 2023 | Trial primary completion date: Apr 2023 --> Dec 2023